New antibody combo shows promise for tough ovarian cancer

NCT ID NCT04938583

Ongoing Disease control Sponsor: CanariaBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a new drug combination for women with recurrent ovarian cancer that has come back after initial treatment. The study includes 54 participants and uses an antibody called oregovomab along with standard chemotherapy and bevacizumab. The goal is to see if this mix is safe and can shrink tumors or slow cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oregovomab (an antibody drug) combined with bevacizumab, paclitaxel, and carboplatin
What this could lead to: If successful, this combination could offer a new treatment option for women with recurrent ovarian cancer who have limited choices.
What could go wrong: This is an early-phase trial with only 54 participants, so results may not apply broadly. The combination also carries risks like side effects from chemotherapy and the antibody.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER BY FIGO STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian cancer ovarian carcinoma peritoneal carcinomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER BY FIGO STAGE OVARIAN CANCER STAGE III OVARIAN CANCER STAGE IV

Contacts and locations

Locations

Asan Medical Hospital

Seoul, Seoul, 05505, South Korea
CHA Bundang Medical Center

Seongnam-si, 13496, South Korea
Korea Anam Hospital

Seoul, Seoul, 02841, South Korea
Kyungpook National University Chilgok Hospital

Daegu, 41404, South Korea
Seoul St. Mary's Hospital

Seoul, Seoul, 06591, South Korea
Severance Hospital

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.